|Bid||2.86 x 200|
|Ask||2.86 x 800|
|Day's Range||2.86 - 2.89|
|52 Week Range||2.25 - 3.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 15, 2017 - Nov 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.21|
NEW YORK, NY / ACCESSWIRE / November 16, 2017 / EDAP TMS SA Sponsored ADR (NASDAQ: EDAP ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 16, 2017 at 8:30 AM ...
EDAP TMS Reports Third Quarter 2017 Results. EDAP's HIFU patient treatment revenues grew 29% compared to third quarter 2016. EDAP received FDA clearance for its Ablatherm Fusion ® late in the quarter. ...
EDAP TMS SA (NASDAQ:EDAP) is a small-cap stock with a market capitalization of USD $89.02M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...
Conference Call to Review Results to be Held Thursday, November 16, 2017. LYON, France, November 01, 2017- EDAP TMS SA, the global leader in therapeutic ultrasound, today announced that it will release ...
LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for EDAP TMS S.A. (NASDAQ: EDAP ) ("EDAP"), following which ...
EDAP to Market Echotherapy for ablation of breast fibroadenomas and benign thyroid nodules. LYON, France, October 9, 2017-- EDAP TMS SA, the global leader in therapeutic ultrasound, today announced the ...
Categories: Yahoo FinanceEDAP TMS SA relative valuation is UNDERVALUED and it has a fundamental analysis score of 63. Our analysis is based on comparing EDAP TMS SA with the following peers – Boston Scientific Corporation, Nephros, Inc., NxStage Medical, Inc. and Rockwell Medical, Inc. (BSX-US, NEPH-US, NXTM-US and RMTI-US). EDAP TMS SA has shown good performance overall, ... Read more (Read more...)
LYON, France, October 4, 2017-- EDAP TMS SA, the global leader in therapeutic ultrasound, today announced FDA approval of its Ablatherm-Fusion device enabling a more precise method for targeting of diagnosed ...
Categories: Yahoo FinanceGet free summary analysis EDAP TMS SA reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of EDAP TMS SA – Nephros, Inc., NxStage Medical, Inc. and Rockwell Medical, Inc. (NEPH-US, NXTM-US and RMTI-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)
University of Chicago Medicine- Dr. A. Shalhav, Chair of Urology Surgery and Director of Robotic Surgery Vituro Health LLC- Dr. S. Scionti, Medical Director and Director of The Scionti Prostate Center ...
NEW YORK, NY / ACCESSWIRE / August 24, 2017 / EDAP TMS SA Sponsored ADR (NASDAQ: EDAP ) will be discussing their earnings results in their Q2 Earnings Call to be held August 24, 2017 at 9:00 AM Eastern ...
Solid expansion across athenahealth's (ATHN) ambulatory, hospital and population health platforms is expected to provide a competitive edge in the niche RCM space.
Intuitive Surgical posted solid numbers in the quarter under review, courtesy of rising customer adoption of procedures and growth in system placements.
AngioDynamics (ANGO) revenues declined year over year in the fourth quarter. Recall of the Acculis product line under the oncology segment is also a concern.
On Jul 17, we issued an updated research report on Kalamazoo, MI-based Stryker Corporation (SYK), one of the largest medical device companies in the global orthopedic market.
Accuray (ARAY) announced its preliminary results for for the fourth quarter and fiscal 2017. Following the announcement, the company's stock lost over 2% in the last trading session to close at $4.70.
Accuray Inc. (ARAY) recently announced that it has signed an agreement with the Neuro Spinal Hospital in Dubai, United Arab Emirates.